To the Editor,

We are delighted to have the opportunity to respond to the letter by Gilks et al. ([@bb0015]). They argue first that historical pathological entities do not map seamlessly to modern day diagnostic categories, which are not only based on expert review by specialist gynecological pathologists but are also increasingly supported by immunohistochemistry (IHC). Second, that the misclassification of biologically indolent tumors as high grade serous (HGS) ovarian cancers may explain the uncharacteristically excellent survival figures we report ([@bb0040]). And third, that our paper may inadvertently lead to the universal screening of HGS ovarian cancers for Lynch syndrome, when this is not indicated.

To address the first point, we undertook contemporary slide review and supporting IHC for a subset of our cases (12/37, 30%). In so doing, we were able to compare the original histological subtype with up-to-date expert gynecological pathology review backed up by IHC. Unfortunately, we were unable to retrieve slides or tissue blocks for all women, particularly those whose surgery was performed elsewhere and more than 15 years ago. [Table 1](#t0005){ref-type="table"} shows the results of our analysis. Pathology review confirmed accurate diagnoses for 10 of the 12 cases (83%), including six endometrioid tumors, one clear cell, one carcinosarcoma, one mixed endometrioid/clear cell tumor and one poorly differentiated carcinoma which was difficult to reliably subtype\* (\*[Fig. 1](#f0005){ref-type="fig"}D). The two discrepant cases were an endometrioid tumor originally misclassified as a 'serous cystadenocarcinoma', and a 'serous papillary carcinoma', which had cytology of low-to-intermediate grade on review and wild type p53 staining favouring a final classification of low grade serous carcinoma\*\* (\*\*[Fig. 1](#f0005){ref-type="fig"}A). Our data are in keeping with those of other case series of Lynch syndrome-associated ovarian cancer, where endometrioid morphology predominates, but clear cell, serous and mixed histotypes are also described ([@bb0020], [@bb0005], [@bb0045], [@bb0035]).Fig. 1Lynch syndrome-associated ovarian tumors with supporting IHC.A) H + E: Low grade serous carcinoma with a glandular, cribriform and papillary architecture, comprising cells with low to intermediate grade cytological atypia. B) Immunohistochemical staining shows loss of MSH2. C) Immunohistochemical staining demonstrates wild-type p53, in keeping with low grade serous carcinoma. D) H + E: Poorly differentiated adenocarcinoma with a glandular and solid architecture. E) Immunohistochemical staining shows loss of MSH2. F) Immunohistochemical staining demonstrates null-type p53.Fig. 1Table 1Contemporary expert gynecological pathology review.Table 1Study IDGermline mutationMMR loss by IHCOriginal histotypeHistology reviewSupporting IHC3MLH1MLH1 & PMS2Clear cellAgreeNot performed4MLH1MLH1EndometrioidAgreeConfirms11MSH2MSH2 & MSH6Poorly differentiated adenocarcinomaAgreeER, PR positive\
Null type p5313MSH2MSH2 & MSH6EndometrioidAgreeConfirms16MSH2MSH2 & MSH6EndometrioidAgreeNot performed19MSH2MSH2 & MSH6Serous papillaryLow grade serousWild type p5320MSH2MSH2 & MSH6EndometrioidAgreeNot performed22MSH2MSH2 & MSH6CarcinosarcomaAgreeConfirms23MSH2MSH2 & MSH6EndometrioidAgreeNot performed27MSH2MSH2 & MSH6Serous cystadenocarcinomaEndometrioidER, PR positive\
WT1 negative\
Wild type p5332MSH6MSH2 & MSH6Mixed clear cell/endometrioidAgreeConfirms37PMS2PMS2MixedAgreeConfirms

Regarding the second point, we speculated that the mismatch repair (MMR) status of the tumors could help differentiate those that had arisen because of mismatch repair deficiency from those that had arisen via a different pathway. As shown in [Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}, all of the tumors showed MMR deficiency in keeping with their inherited mutation, including the women whose tumors showed serous morphology. This supports the hypothesis that all have arisen as a consequence of Lynch syndrome. We and others have shown that Lynch syndrome-associated ovarian cancer presents at an earlier age and stage and demonstrates excellent survival rates compared with sporadic ovarian cancers ([@bb0030], [@bb0025]). This may be due to early detection through surveillance, good biology, enhanced tumor immunogenicity and responsiveness to current treatments ([@bb0025]). By contrast, BRCA-associated ovarian cancers have a poor prognosis irrespective of early detection and treatment ([@bb0010]). There is no doubt that germline mutations in MMR and BRCA genes are only similar because they both predispose a woman to developing ovarian cancer; in every other respect, they are quite different.

Finally, we do not recommend that all HGS ovarian cancers are routinely screened for Lynch syndrome. The prevalence of Lynch syndrome in women with ovarian cancer is low. However, genetic predisposition syndromes should always be considered as an underlying cause for non-mucinous invasive epithelial ovarian cancer in young women, those with a strong family history of breast, endometrial, ovarian and/or colorectal cancer, or those with metachronous or synchronous cancers. And indeed, in the spirit of P4 medicine, the sequencing panel chosen should reflect the unique clinical context of each individual woman, rather than being driven purely by tumor histotype.
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